Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 3/20 | 0.67 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.67 |
| ▸ | MEN1 | O00255 | 1/20 | 0.67 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.66 |
| ▸ | PDE3B | Q13370 | 5/20 | 0.56 |
| ▸ | PDE3A | Q14432 | 5/20 | 0.56 |
| ▸ | MAPT | P10636 | 1/20 | 0.53 |
| ▸ | PDE4A | P27815 | 3/20 | 0.51 |
| ▸ | PDE4B | Q07343 | 3/20 | 0.51 |
| ▸ | PDE4C | Q08493 | 3/20 | 0.51 |
| ▸ | PDE4D | Q08499 | 3/20 | 0.51 |
| ▸ | METAP2 | P50579 | 1/20 | 0.46 |
| ▸ | HRH3 | Q9Y5N1 | 6/20 | 0.44 |
| ▸ | TP53 | P04637 | 1/20 | 0.43 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.43 |
| ▸ | HPGD | P15428 | 1/20 | 0.43 |
| ▸ | TSHR | P16473 | 1/20 | 0.43 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.43 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.43 |
| ▸ | BLM | P54132 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3452908 | 0.89 | LMNA (0.80) | LMNAKMT2AMEN1CYP1A2PDE3B | |
| SCHEMBL9687063 | 0.82 | LMNA (0.69) | LMNAKMT2AMEN1CYP1A2PDE3B | |
| SCHEMBL928226 | 0.80 | LMNA (0.67) | LMNAKMT2AMEN1CYP1A2PDE3B | |
| SCHEMBL481916 | 0.80 | LMNA (0.67) | LMNAKMT2AMEN1CYP1A2PDE3B | |
| SCHEMBL11035831 | 0.80 | LMNA (1.00) | LMNAKMT2AMEN1CYP1A2PDE3B | |
| SCHEMBL1392640 | 0.80 | LMNA (0.67) | LMNAKMT2AMEN1CYP1A2PDE3B | |
| SCHEMBL4122238 | 0.80 | LMNA (0.67) | LMNAKMT2AMEN1CYP1A2PDE3B | |
| SCHEMBL2152989 | 0.80 | LMNA (0.67) | LMNAKMT2AMEN1CYP1A2PDE3B | |
| SCHEMBL482059 | 0.79 | CYP1A2 (1.00) | LMNAKMT2AMEN1CYP1A2PDE3B | |
| Hydrochloric Acid SCHEMBL7316011 | 0.78 | LMNA (0.65) | LMNAKMT2AMEN1CYP1A2PDE3B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8367668-B2 | Pyridazinone derivatives | MERCK Patent Gesellschaft mit beschränkter Haftung (DE) | 2013-02-05 | — | — | US | disclosed |
| US-8367668-B2 | Pyridazinone derivatives | MERCK Patent Gesellschaft mit beschränkter Haftung (DE) | 2013-02-05 | — | — | US | disclosed |
| US-8367668-B2 | Pyridazinone derivatives | MERCK Patent Gesellschaft mit beschränkter Haftung (DE) | 2013-02-05 | — | — | US | disclosed |
| CN-101679303-B | Pyridazinone derivatives | MERCK PATENT GMBH | 2012-05-09 | — | — | CN | disclosed |
| EP-2316836-A1 | Substituted diazabicycloalkane derivatives as ligands at alpha 7 nicotinic acetylcholine receptors | Abbott Laboratories (US) | 2011-05-04 | — | — | EP | disclosed |
| US-7872010-B2 | Substituted diazabicycloalkane derivatives having affinity for nicotinic acetylcholine receptors | ABBOTT LABORATORIES (US) | 2011-01-18 | — | — | US | disclosed |
| US-20100179148-A1 | PYRIDAZINONE DERIVATIVES | MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DE) | 2010-07-15 | — | — | US | disclosed |
| US-20100179148-A1 | PYRIDAZINONE DERIVATIVES | MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DE) | 2010-07-15 | — | — | US | disclosed |
| US-20100179148-A1 | PYRIDAZINONE DERIVATIVES | MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DE) | 2010-07-15 | — | — | US | disclosed |
| CN-101679303-A | pyridazinone derivatives | MERCK PATENT GMBH | 2010-03-24 | — | — | CN | disclosed |
| US-7399765-B2 | Substituted diazabicycloalkane derivatives | ABBOTT LABORATORIES (US) | 2008-07-15 | — | — | US | disclosed |
| CN-101189233-A | Substituted diazabicycloalkane derivatives as ligands for the alpha 7 nicotinic acetylcholine receptor | ABBOTT LAB (US) | 2008-05-28 | — | — | CN | disclosed |
| US-7309699-B2 | 3-Quinuclidinyl amino-substituted biaryl derivatives | ABBOTT LABORATORIES (US) | 2007-12-18 | — | — | US | disclosed |
| US-20070275975-A1 | 3-QUINUCLIDINYL AMINO-SUBSTITUTED BIARYL DERIVATIVES | JI JIANGUO | 2007-11-29 | — | — | US | disclosed |
| EP-1699785-A2 | 3-QUINUCLIDINYL AMINO-SUBSTITUTED BIARYL DERIVATIVES | ABBOTT LABORATORIES (US) | 2006-09-13 | — | — | EP | disclosed |
| EP-1664045-A1 | SUBSTITUTED DIAZABICYCLOALKANE DERIVATIVES AS LIGANDS AT ALPHA 7 NICOTINIC ACETYLCHOLINE RECEPTORS | Abbott Laboratories (US) | 2006-06-07 | — | — | EP | disclosed |
| WO-2005066166-A2 | 3-QUINUCLIDINYL AMINO-SUBSTITUTED BIARYL DERIVATIVES | ABBOTT LABORATORIES (US) | 2005-07-21 | — | — | WO | disclosed |
| US-20050159597-A1 | 3-Quinuclidinyl amino-substituted biaryl derivatives | ABBOTT LABORATORIES | 2005-07-21 | — | — | US | disclosed |
| US-20050101602-A1 | For example, 3-(6-phenyl-pyridazin-3-yl)-3,8-diaza-bicyclo[3.2.1]octane; for treatment or prevention of conditions and disorders related to nAChR activity, and more particularly alpha 7 nAChR activity, such as attention deficit disorder, attention deficit hyperactivity disorder, Alzheimer's disease | ABBVIE INC. | 2005-05-12 | — | — | US | disclosed |
| WO-2005028477-A1 | SUBSTITUTED DIAZABICYCLOALKANE DERIVATIVES AS LIGANDS AT ALPHA 7 NICOTINIC ACETY LCHOLINE RECEPTORS | ABBOTT LABORATORIES (US) | 2005-03-31 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100179148-A1 | PYRIDAZINONE DERIVATIVES | MET, ERBB2, RET | LMNA 2650/4885KMT2A 1002/4885MEN1 121/4885 |
| US-20050159597-A1 | 3-Quinuclidinyl amino-substituted biaryl derivatives | CHRNA7, CHRNA9, CHRNA1 | LMNA 1775/4885KMT2A 1742/4885MEN1 4420/4885 |
| US-20070275975-A1 | 3-QUINUCLIDINYL AMINO-SUBSTITUTED BIARYL DERIVATIVES | CHRNA7, CHRNA9, CHRNA1 | LMNA 1775/4885KMT2A 1742/4885MEN1 4420/4885 |
| US-20050101602-A1 | For example, 3-(6-phenyl-pyridazin-3-yl)-3,8-diaza-bicyclo[3.2.1]octane; for treatment or prevention of conditions and disorders related to nAChR activity, and more particularly alpha 7 nAChR activity, such as attention deficit disorder, attention deficit hyperactivity disorder, Alzheimer's disease | CHRNA7, CHRNA2, CHRNA6 | LMNA 3433/4885KMT2A 1571/4885MEN1 4343/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.